Search | Clinical Trials Finder

Conditions: Human Immunodeficiency Virus
Interventions: Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention; Device · Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections, Hepatitis
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Stanford, California • Miami, Florida • Honolulu, Hawaii + 7 more

Conditions: HIV, Hepatitis C
Interventions: dolutegravir, simeprevir; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections
Interventions: Peginterferon a-2a plus Ribavirin; Drug
Lead sponsor: Hepatitis Resource Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C Virus, HIV
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more

Conditions: Substance-related Disorders
Interventions: On-site bundled rapid HIV/HCV testing, Standard of care (SOC); Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Hepatitis C
Interventions: Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Hepatitis c
Interventions: Leap-c group intervention; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: HIV Infections, Hepatitis C Virus Infection
Interventions: Virtual Community Intervention, Standard of Care; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 99 Years
Enrollment: 511 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hiv, Hepatitis C
Interventions: Persuasive Health Communication Intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder
Interventions: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC); Behavioral
Lead sponsor: Elana Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more

Conditions: Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions: Suboxone, Truvada, Mavyret; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Greensboro, North Carolina

Conditions: HIV, Hepatitis C
Interventions: Questionnaire, Rapid finger stick, Venipuncture; Behavioral · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Hepatitis C
Interventions: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: HIV, Hepatitis C, Cirrhosis
Interventions: Harvoni; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Nitazoxanide With Pegylated Interferon And Ribavirin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hepatitis B, Hepatitis C, HIV Infection
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 3,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Heroin Dependence
Interventions: Buprenorphine/naloxone, pegInterferon; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Chronic Mental Illness, Chronic Physical Illness
Interventions: Patient-Directed Wellness Account, Health Navigator; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 55 Years
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions: Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening); Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 79 Years
Enrollment: 6,466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: HCV Coinfection, Liver Disease, HIV
Interventions: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Immunodeficiency Virus, Hepatitis C
Interventions: EBR/GZR; Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 40 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV, Hepatitis C, Substance Use Disorders
Interventions: CJC-TraC; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Oregon, Wisconsin • Union Grove, Wisconsin

Search by objective public record fields.

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

HIV-HCV Coinfection: Impact of Immune Dysfunction

Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults

Digital Community to Improve Health in Rural Areas

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

Integrating HCV and HIV Screening During the Era of HIV Antigen Testing

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

deLIVER: Direct Acting Antiviral Effects on the Liver

Impact of Hepatitis C Therapy and Bone Health

Criminal Justice Coordinated Transitional Care